4-ACETAMIDOPHENYL-2-[{2-(NITROOXY)ETHYL}(4-NITROPHENYL)AMINO]BENZOATE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FSAWICRPWXBQJA-UHFFFAOYSA-N
Smiles	CC(=O)Nc1ccc(OC(=O)c2ccccc2N(CCO[N+](=O)[O-])c3ccc(cc3)[N+](=O)[O-])cc1
InChI	InChI=1S/C23H20N4O8/c1-16(28)24-17-6-12-20(13-7-17)35-23(29)21-4-2-3-5-22(21)25(14-15-34-27(32)33)18-8-10-19(11-9-18)26(30)31/h2-13H,14-15H2,1H3,(H,24,28)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H20N4O8
Molecular Weight	480.43
AlogP	5.9
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	11.0
Polar Surface Area	159.51
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	35.0

Assay Description	Organism	Bioactivity
Ulcerogenic activity in fasted albino Rattus norvegicus (rat) assessed as stomach mucosal injury at 13 mg/kg, po administered QD for 3 days measured on day 4 by electron microscopic analysis	Rattus norvegicus	None
Induction of nitric oxide release in phosphate buffer at 10'-4 M after 1 hr at pH 7.4 by Griess method in presence of L-cysteine relative to control	None	6.98 %
Ulcerogenic activity in fasted albino Rattus norvegicus (rat) at 13 mg/kg, po administered QD for 3 days measured on day 4	Rattus norvegicus	None
Analgesic activity in Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 13 mg/kg, po measured after 25 min relative to control	Mus musculus	13.8 %
Anti-inflammatory activity in Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 13 mg/kg, po administered at 1 hr prior to carrageenan-challenge measured after 4 hr relative to control	Rattus norvegicus	32.11 %
Anti-inflammatory activity in Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 13 mg/kg, po administered at 1 hr prior to carrageenan-challenge measured after 3 hr relative to control	Rattus norvegicus	23.32 %
Anti-inflammatory activity in Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 13 mg/kg, po administered at 1 hr prior to carrageenan-challenge measured after 2 hr relative to control	Rattus norvegicus	11.95 %
Anti-inflammatory activity in Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 13 mg/kg, po administered at 1 hr prior to carrageenan-challenge measured after 1 hr relative to control	Rattus norvegicus	6.67 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2296733
PubChem	76313152

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).